Encinitas, CA, United States of America

Jerry L Ware

This inventor holds 4 USPTO granted patents, plus 1 CIPO patent. Top assignee: Scripps Research Institute. Active years: 1994-1999.


% Patents Active = 100.0


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 1994-1999

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Jerry L. Ware: Innovator in Therapeutic Polypeptides

Introduction

Jerry L. Ware is a prominent inventor based in Encinitas, California. He has made significant contributions to the field of therapeutic polypeptides, holding a total of 4 patents. His work focuses on innovative methods for treating thrombosis and improving platelet transfusion outcomes.

Latest Patents

Among his latest patents is a groundbreaking invention related to therapeutic domains of von Willebrand factor. This polypeptide is capable of inhibiting the binding of von Willebrand factor to platelets, which is crucial in managing blood clotting disorders. Another notable patent involves antibodies and immunoassays for detecting platelet transfusion refractoriness. This method enhances the effectiveness of platelet transfusions by ensuring compatibility between donor and recipient platelets.

Career Highlights

Jerry L. Ware is affiliated with The Scripps Research Institute, where he conducts his research and development. His work has been instrumental in advancing the understanding of platelet biology and therapeutic interventions.

Collaborations

Jerry has collaborated with notable professionals in his field, including Zaverio M. Ruggeri. Their joint efforts have contributed to the development of innovative solutions in the realm of hematology.

Conclusion

Jerry L. Ware's contributions to the field of therapeutic polypeptides and platelet transfusion are noteworthy. His innovative patents and collaborations continue to impact medical science positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…